phage-encoded colanic acid-degrading enzyme permits lytic phage: Infection of a capsule-forming resistant mutant Escherichia coli strain

Applied and Environmental Microbiology

Volumn 81, Issue 3, 2015, Pages 900-909

  Kim, Min Soo ^a   Kim, Young Deuk ^a   Hong, Sung Sik ^a   Park, Kwangseo ^a   Ko, Kwan Soo ^b   Myung, Heejoon ^a,c  

^a Hankuk University of Foreign Studies   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Export Import Bank of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGES; BIOFILMS; ENZYMES; GENES;

BACTERIAL COLONIES; CAPSULE FORMATION; CLINICAL ISOLATES; DEGRADING ENZYMES; MICROARRAY ANALYSIS; OPEN READING FRAME; RESISTANT BACTERIA; RESISTANT MUTANTS;

ESCHERICHIA COLI;

BACTERIOPHAGE; BIOFILM; ENZYME ACTIVITY; GENE EXPRESSION; INCUBATION; MICROBIAL ACTIVITY; MUTATION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

COLANIC ACID; POLYSACCHARIDE;

BACTERIAL CAPSULE; COLIPHAGE; ENZYMOLOGY; ESCHERICHIA COLI; GENE EXPRESSION PROFILING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HYDROLYSIS; METABOLISM; MICROARRAY ANALYSIS; VIROLOGY;

BACTERIAL CAPSULES; COLIPHAGES; ESCHERICHIA COLI; GENE EXPRESSION PROFILING; HYDROLYSIS; MICROARRAY ANALYSIS; POLYSACCHARIDES;

EID: 84921364702     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.02606-14     Document Type: Article

References (43)

1. Alekshun MN, Levy SB. 2007. Molecular mechanisms of antibacterial multidrug resistance. Cell 128:1037-1050. http://dx.doi.org/10.1016/j.cell.2007.03.004.
2. Mathur MD, Vidhani S, Mehndiratta PL. 2003. Bacteriophage therapy: an alternative to conventional antibiotics. J Assoc Physicians India 51: 593-596.
3. Skurnik M, Strauch E. 2006. Phage therapy: facts and fiction. Int J Med Microbiol 296:5-14. http://dx.doi.org/10.1016/j.ijmm.2005.09.002.
4. Sulakvelidze A, Alavidze Z, Morris JG, Jr. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45:649-659. http://dx.doi.org/10.1128/AAC.45.3.649-659.2001.
5. Abedon ST, Thomas-Abedon C. 2010. Phage therapy pharmacology. Curr Pharm Biotechnol 11:28-47. http://dx.doi.org/10.2174/138920110790725410.
6. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol 8:769-783. http://dx.doi.org/10.2217/fmb.13.47.
7. Loc-Carrillo C, Abedon ST. 2011. Pros and cons of phage therapy. Bacteriophage 1:111-114. http://dx.doi.org/10.4161/bact.1.2.14590.
8. Skurnik M, Pajunen M, Kiljunen S. 2007. Biotechnological challenges of phage therapy. Biotechnol Lett 29:995-1003. http://dx.doi.org/10.1007/s10529-007-9346-1.
9. Hong SS, Jeong J, Lee J, Kim S, Min WG, Myung H. 2013. Therapeutic effects of bacteriophages against Salmonella gallinarum infection in chickens. J Microbiol Biotechnol 23:1478-1483. http://dx.doi.org/10.4014/jmb.1304.04067.
10. Labrie SJ, Samson JE, Moineau S. 2010. Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317-327. http://dx.doi.org/10.1038/nrmicro2315.
11. Nordström K, Forsgren A. 1974. Effect of protein A on adsorption of bacteriophages to Staphylococcus aureus. J Virol 14:198-202.
12. Marraffini LA, Sontheimer EJ. 2008. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322:1843-1845. http://dx.doi.org/10.1126/science.1165771.
13. Wilson GG, Murray NE. 1991. Restriction and modification systems. Annu Rev Genet 25:585-627. http://dx.doi.org/10.1146/annurev.ge.25.120191.003101.
14. Gottesman S, Stout V. 1991. Regulation of capsular polysaccharide synthesis in Escherichia coli K12. Mol Microbiol 5:1599-1606. http://dx.doi.org/10.1111/j.1365-2958.1991.tb01906.x.
15. Sledjeski DD, Gottesman S. 1996. Osmotic shock induction of capsule synthesis in Escherichia coli K-12. J Bacteriol 178:1204-1206.
16. Clarke DJ. 2010. The Rcs phosphorelay: more than just a two-component pathway. Future Microbiol 5:1173-1184. http://dx.doi.org/10.2217/fmb.10.83.
17. Stevenson G, Andrianopoulos K, Hobbs M, Reeves PR. 1996. Organization of the Escherichia coli K-12 gene cluster responsible for production of the extracellular polysaccharide colanic acid. J Bacteriol 178:4885-4893.
18. Stout V, Gottesman S. 1990. RcsB and RcsC: a two-component regulator of capsule synthesis in Escherichia coli. J Bacteriol 172:659-669.
19. Ebel W, Trempy JE. 1999. Escherichia coli RcsA, a positive activator of colanic acid capsular polysaccharide synthesis, functions to activate its own expression. J Bacteriol 181:577-584.
20. Trisler P, Gottesman S. 1984. lon transcriptional regulation of genes necessary for capsular polysaccharide synthesis in Escherichia coli K-12. J Bacteriol 160:184-191.
21. Kim MS, Hong SS, Park K, Myung H. 2013. Genomic analysis of bacteriophage PBECO4 infecting Escherichia coli O157:H7. Arch Virol 158:2399-2403. http://dx.doi.org/10.1007/s00705-013-1718-3.
22. Sambrook J, Russell DW. 2006. Purification of bacteriophage particles by centrifugation through a glycerol step gradient. CSH Protoc 2006: pdb.prot3969. http://dx.doi.org/10.1101/pdb.prot3969.
23. Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. 2009. Enumeration of bacteriophages by double agar overlay plaque assay. Methods Mol Biol 501:69-76. http://dx.doi.org/10.1007/978-1-60327-164-6_7.
24. Zhang XS, Garcia-Contreras R, Wood TK. 2008. Escherichia coli transcription factor YncC (McbR) regulates colanic acid and biofilm formation by repressing expression of periplasmic protein YbiM (McbA). ISME J 2:615-631. http://dx.doi.org/10.1038/ismej.2008.24.
25. Knezevic P, Obreht D, Curcin S, Petrusic M, Aleksic V, Kostanjsek R, Petrovic O. 2011. Phages of Pseudomonas aeruginosa: response to environmental factors and in vitro ability to inhibit bacterial growth and biofilm formation. J Appl Microbiol 111:245-254. http://dx.doi.org/10.1111/j.1365-2672.2011.05043.x.
26. Knezevic P, Petrovic O. 2008. A colorimetric microtiter plate method for assessment of phage effect on Pseudomonas aeruginosa biofilm. J Microbiol Methods 74:114-118. http://dx.doi.org/10.1016/j.mimet.2008.03.005.
27. Danese PN, Pratt LA, Kolter R. 2000. Exopolysaccharide production is required for development of Escherichia coli K-12 biofilm architecture. J Bacteriol 182:3593-3596. http://dx.doi.org/10.1128/JB.182.12.3593-3596.2000.
28. Filippov AA, Sergueev KV, He Y, Huang XZ, Gnade BT, Mueller AJ, Fernandez-Prada CM, Nikolich MP. 2011. Bacteriophage-resistant mutants in Yersinia pestis: identification of phage receptors and attenuation for mice. PLoS One 6:e25486. http://dx.doi.org/10.1371/journal.pone.0025486.
29. Silver RP, Vimr ER. 1990. Polysialic acid capsule of E. coli K1, p 39-60. In Iglewski BH, Clark VL (ed), The bacteria: a treatise on structure and function, vol 11. Molecular basis of bacterial pathogenesis. Academic Press, Inc, New York, NY.
30. Scholl D, Adhya S, Merril C. 2005. Escherichia coli K1's capsule is a barrier to bacteriophage T7. Appl Environ Microbiol 71:4872-4874. http://dx.doi.org/10.1128/AEM.71.8.4872-4874.2005.
31. Whitfield C, Roberts IS. 1999. Structure, assembly and regulation of expression of capsules in Escherichia coli. Mol Microbiol 31:1307-1319. http://dx.doi.org/10.1046/j.1365-2958.1999.01276.x.
32. Radke KL, Siegel EC. 1971. Mutation preventing capsular polysaccharide synthesis in Escherichia coli K-12 and its effect on bacteriophage resistance. J Bacteriol 106:432-437.
33. Steven AC, Trus BL, Maizel JV, Unser M, Parry DA, Wall JS, Hainfeld JF, Studier FW. 1988. Molecular substructure of a viral receptorrecognition protein. The gp17 tail-fiber of bacteriophage T7. J Mol Biol 200:351-365.
34. Lu TK, Collins JJ. 2007. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104:11197-11202. http://dx.doi.org/10.1073/pnas.0704624104.
35. Prigent-Combaret C, Prensier G, Le Thi TT, Vidal O, Lejeune P, Dorel C. 2000. Developmental pathway for biofilm formation in curliproducing Escherichia coli strains: role of flagella, curli and colanic acid. Environ Microbiol 2:450-464. http://dx.doi.org/10.1046/j.1462-2920.2000.00128.x.
36. Moons P, Faster D, Aertsen A. 2013. Lysogenic conversion and phage resistance development in phage exposed Escherichia coli biofilms. Viruses 5:150-161. http://dx.doi.org/10.3390/v5010150.
37. Pei R, Lamas-Samanamud GR. 2014. Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl Environ Microbiol 80:5340 -5348. http://dx.doi.org/10.1128/AEM.01434-14.
38. Hanna A, Berq M, Stout V, Razatos A. 2003. Role of capsular colanic acid in adhesion of uropathogenic Escherichia coli. Appl Environ Microbiol 69:4474 -4481. http://dx.doi.org/10.1128/AEM.69.8.4474-4481.2003.
39. Hsu CR, Lin TL, Pan YJ, Hsieh PF, Wang JT. 2013. Isolation of a bacteriophage specific for a new capsular type of Klebsiella pneumoniae and characterization of its polysaccharide depolymerase. PLoS One 8:e70092. http://dx.doi.org/10.1371/journal.pone.0070092.
40. Qin L, Kida Y, Imamura Y, Kuwano K, Watanabe H. 2013. Impaired capsular polysaccharide is relevant to enhanced biofilm formation and lower virulence in Streptococcus pneumoniae. J Infect Chemother 19:261-271. http://dx.doi.org/10.1007/s10156-012-0495-3.
41. Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, Schultz LW, Umland TC, Campagnari AA. 2010. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun 78:3993-4000. http://dx.doi.org/10.1128/IAI.00366-10.
42. Fischer S, Kittler S, Klein G, Glünder G. 2013. Impact of a single phage and a phage cocktail application in broilers on reduction of Campylobacter jejuni and development of resistance. PLoS One 8:e78543. http://dx.doi.org/10.1371/journal.pone.0078543.
43. Gu J, Liu X, Li Y, Han W, Lei L, Yang Y, Zhao H, Gao Y, Song J, Lu R, Sun C, Feng X. 2012. A method for generation phage cocktail with great therapeutic potential. PLoS One 7:e31698. http://dx.doi.org/10.1371/journal.pone.0031698.